Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Q32 Bio Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
5.32
1.67
2.7
34
3.21
1.16
0
53.7
Research and development
21.4
47.9
89.4
100
93.1
98.4
31.7
48.1
19.2
General and administrative
8.28
17.3
22.2
32.6
36.8
38.1
9.88
18
17.7
Operating expenses
29.7
65.2
112
133
130
136
41.6
66.1
36.8
Operating income
-29.7
-59.9
-110
-130
-95.9
-133
-48.3
-66.1
16.9
Interest expense
1.5
Other non-operating income
-0.33
4.35
6.03
1.57
0.19
134
-5.17
20
12.9
Pre-tax income
-95.8
1.2
-87.1
-46.1
29.8
Income tax
0
0
0
0
0
0.72
0.32
0.02
0
Net income
-30
-55.6
-104
-129
-95.8
-5.01
-53.7
-47.7
29.8
EBITDA
-29
-58.6
-104
-122
-87.6
-132
-47.8
-65.6
17.3
EPS, basic
-955.34
-153.96
-195.02
-221.07
-136.59
-7.11
-153.96
-5.12
2.42
EPS, diluted
-955.34
-153.96
-195.02
-221.07
-136.59
-7.11
-153.96
-6.58
2.42
Shares, basic (weighted)
0.03
0.36
0.53
0.58
0.7
0.73
0.35
9.32
12.3
Shares, diluted (weighted)
0.03
0.36
0.53
0.58
0.7
0.73
0.35
9.66
12.3
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
51.6
38.2
53.8
217
108
34
25.6
78
48.3
Short-term investments
78.1
177
209
0
47.5
141
0
0
Other current assets
1.95
6.95
4.19
2.13
7.13
5.99
0.08
0.4
0.02
Total current assets
132
222
267
220
192
181
28.7
81.9
55.1
Property, plant and equipment
3.15
35.6
42.7
37
2.25
1.08
1.78
1.37
0.98
Lease right-of-use assets
5.9
15.6
20.6
6.3
5.72
5.1
Other non-current assets
4.61
0.12
0
Total assets
138
259
311
264
212
228
47.1
92.3
61.8
Accounts payable
2.54
15.7
2.61
4.72
2.37
1.14
3.47
2.99
0.88
Accrued liabilities
1.44
3.37
4.55
6.9
7.81
5.95
9.76
7.48
4.23
Deferred revenue
3.34
0.77
0.81
5.63
3.21
1.16
0
Total current liabilities
8.86
22.5
12.4
22.7
17.2
22.6
14.1
16.5
11.3
Lease liabilities
12.9
23.7
27.9
6.25
5.64
4.94
Other non-current liabilities
55
55
0
Total liabilities
39.2
62.7
52.1
67.7
42.1
50.5
119
86.7
19.8
Paid-in capital
0.8
292
458
524
594
608
4.16
240
247
Retained earnings
-40.2
-95.8
-200
-328
-424
-429
-187
-235
-205
Other comprehensive income
-0.07
-0.08
0.18
0
-0.01
-0.4
0
0
Shareholders' equity
-39.5
196
259
196
170
-131
-183
5.68
42
Total equity
-39.5
196
259
196
170
-131
-183
5.68
42
Total liabilities and equity
138
259
311
264
212
228
47.1
92.3
61.8
Shares outstanding
0.03
0.47
0.57
0.64
0.72
0.73
0.36
12.2
12.9
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-30
-55.6
-104
-129
-95.8
-5.01
-113
-47.7
29.8
Depreciation and amortization
0.68
1.29
6.32
7.97
8.35
1.29
0.5
0.49
0.39
Stock-based compensation
0.28
2.62
7.64
13.2
17.2
13.1
1.43
4.39
5.26
Deferred income tax
0.3
0.1
Change in payables
1.72
4.38
-4.45
2.46
-2.49
-0.98
2.03
-1.04
-2.11
Cash from operations
6.48
-42.6
-91.4
-94.3
-110
-114
-18.7
-67.7
-33.5
Capital expenditures
-1.96
-24.9
-21.8
-3.73
-2.4
-1.29
-0.01
-0.08
0
Purchases of investments
-78.1
-245
-286
-20
-97.4
-157
-73.2
Sales and maturities of investments
148
256
229
49
65.5
174
Cash from investing
-81.5
-122
-51.8
205
-50.8
36.7
-0.01
19.9
7
Stock issued
0.09
135
0.18
49.7
0
0
42
0
Cash from financing
115
151
158
53.1
52.2
0.6
0.41
95.1
-3.13
Net change in cash
40.2
-13.4
15.1
164
-108
-76.3
5.28
47.3
-29.7
Free cash flow
4.52
-67.5
-113
-98.1
-112
-115
-18.7
-67.8
-33.5
Income taxes paid
0
0.72
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.77 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
31.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
29.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
155.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
81.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
640.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
-26.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-33.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-35.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-25.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
27.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
156.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
84.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
20.3x
Current assets / current liabilities.
Quick ratio
19.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
19.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.97
Cash from operations / diluted weighted shares.
Book value per share
$4.46
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
7.73x
Market cap / net income. Only when net income is positive.
P/B
2.47x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.47x
Market cap / tangible book value, when positive.
EV/EBIT
7.21x
Enterprise value / operating income, when both are positive.
EV/EBITDA
7.09x
Enterprise value / EBITDA, when both are positive.
Earnings yield
12.9%
Net income / market cap (the inverse of P/E).
What was Q32 Bio Inc.'s revenue in fiscal 2025?
Q32 Bio Inc. reported revenue of $53.7M for fiscal 2025.
Was Q32 Bio Inc. profitable in fiscal 2025?
Yes. Net income was $29.8M, a net margin of 55.5%.
How much free cash flow did Q32 Bio Inc. generate in fiscal 2025?
Cash from operations of $33.5M minus capital expenditures of $0.0 left free cash flow of -$33.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.